Electra Therapeutics filed for an IPO on Nasdaq to fund clinical development of its immunology and cancer pipeline. The company plans to list under ticker ETRA and intends to deploy proceeds to advance ipsoprubart (sHLH) through its global phase 2/3 trial and pursue development steps toward potential regulatory submissions and commercialization readiness. Electra reported that ipsoprubart achieved a 100% overall survival at eight weeks in a prior phase 1b cohort of 12 frontline patients and has received both FDA breakthrough therapy and EMA PRIME designations for sHLH. The IPO filing also outlines plans to advance ELA822 in early human studies. The filing continues the 2026 IPO pipeline for specialty biotechs using non-dilutive funding strategies earlier in development to reach key late-stage milestones.